Sapan Ghai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXPD.L Regulatory News (XPD)

  • There is currently no data for XPD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) - Xpediator plc - Replacement

5 Jan 2023 13:14

RNS Number : 8442L
Cogels Investments Limited
05 January 2023
 

Replacement - Form 8 (OPD) - Xpediator plc

 

This announcement replaces the Form 8 (OPD) announcement released by Cogels Investments Limited on 4 January 2023 at 15:14 (GMT) under RNS 7035L.

 

Sections 1, 2, 3 and 4 have been updated.

 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

A consortium comprising Cogels Investments Limited, funds managed by BaltCap and Justas Versnickas.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Cogels Investments Limited, the investment vehicle of Stephen Blyth.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Xpediator plc

(d) Is the discloser the offeror or the offeree?

Offeror

(e) Date position held:

The latest practicable date prior to the disclosure

30 December 2022

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

5p ordinary shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

37,260,660*

 

26.30

 

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

 

TOTAL:

37,260,660

26.30

 

 

 

All interests and all short positions should be disclosed.

\* The relevant securities referred to above are held directly by Cogels Investments Limited.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

The persons listed below are either a director of Cogels Investments Limited or a close relative of a director of Cogels Investments Limited.

 

Name

Number of ordinary shares of 5p each held

Percentage of issued share capital

Lucia Blyth

104,077

0.07%

Claudia Blyth

104,077

0.07%

Olivia Blyth

104,077

0.07%

Emilia Blyth

104,077

0.07%

George Blyth

104,077

0.07%

Frances Lee

31,223

0.02%

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None.

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None.

 

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

 

 

Date of disclosure:

5 January 2023

Contact name:

Stephen Blyth

Telephone number:

+44 7801 662486

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEEBAMJTMTMMBLJ
Date   Source Headline
4th Jan 20236:20 pmRNSForm 8.3 - Xpediator plc
4th Jan 20233:14 pmRNSForm 8 (OPD) - Xpediator plc
21st Dec 202210:29 amRNSForm 8.3 - Xpediator plc
20th Dec 202211:05 amRNSSecond Price Monitoring Extn
20th Dec 202211:00 amRNSPrice Monitoring Extension
20th Dec 20229:41 amRNSForm 8.3 - Xpediator plc
20th Dec 20227:00 amRNSAnnouncement regarding possible offer
3rd Nov 20227:00 amRNSQ3 Trading Update
27th Sep 20229:05 amRNSSecond Price Monitoring Extn
27th Sep 20229:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSHalf-year Report
20th Sep 20227:00 amRNSNotice of Interim Results & Investor Presentation
10th Jun 202212:56 pmRNSResult of AGM
9th Jun 20227:00 amRNSAGM Statement
1st Jun 20227:00 amRNSBoard updates
17th May 20228:15 amRNSNotice of AGM
17th May 20227:00 amRNSDirectorate Change
4th Apr 20227:00 amRNSFinal Results
28th Mar 20227:00 amRNSNotice of Results
25th Mar 20224:17 pmRNSDirectorate Change
31st Jan 20227:00 amRNSTrading Update
19th Jan 20227:00 amRNSChange of Adviser
17th Jan 20227:00 amRNSNew Warehouse
22nd Nov 20211:00 pmRNSDirectorate Change
13th Sep 20217:00 amRNSInterim Results
8th Sep 20217:00 amRNSNotice of Results
6th Aug 20217:00 amRNSStrategic Partnership
6th Jul 20217:00 amRNSExercise of Warrants
25th Jun 20217:00 amRNSTrading Statement
8th Jun 20213:30 pmRNSResult of AGM
8th Jun 20217:00 amRNSAGM Statement
25th May 20217:00 amRNSUpdated Ex-Dividend and Record Dates
12th May 20217:00 amRNSPosting of Annual Report and Notice of AGM
12th Apr 20217:00 amRNSFinal Results
7th Apr 20217:00 amRNSNotice of Results and Investor Presentation
3rd Mar 20217:00 amRNSDirector/PDMR Shareholding
19th Feb 202111:05 amRNSSecond Price Monitoring Extn
19th Feb 202111:00 amRNSPrice Monitoring Extension
5th Feb 20217:00 amRNSLaunch of CSOP and Issue of awards to Director
29th Jan 202111:06 amRNSSecond Price Monitoring Extn
29th Jan 202111:00 amRNSPrice Monitoring Extension
29th Jan 20217:00 amRNSTrading Statement
19th Jan 20217:00 amRNSDirectorate Change
31st Dec 20207:00 amRNSDisposal
1st Dec 20207:00 amRNSInvestor Presentation
23rd Nov 20207:00 amRNSTrading Statement
10th Nov 20204:41 pmRNSSecond Price Monitoring Extn
10th Nov 20204:36 pmRNSPrice Monitoring Extension
6th Oct 20207:00 amRNSAcquisition
1st Oct 20207:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.